REGENERON PHARMACEUTICALS, INC.
Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures and commercializes medicines for people with serious diseases. Its products and development programs address eye, allergic and inflammatory, cancer, cardiovascular and metabolic, neurological, hematologic, infectious and rare diseases. Regeneron’s marketed products include EYLEA and EYLEA HD, Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Ordspono and Lynozyfic. It also conducts clinical and preclinical research and develops product candidates with collaborators. Regeneron makes money through product sales and collaboration arrangements. It records sales for some products itself, while collaborators or licensees record sales for others; Regeneron also receives shares of profits or royalties under certain arrangements. Regeneron is headquartered in Tarrytown, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Pfizer reported Q3 revenue of $16.6bn, raising its 2026 revenue guidance to $62bn-$64bn. Regeneron reported a 36% revenue increase to $5.1bn. The Lancet warns of accelerating health impacts of climate change. Cancer Research UK partners with WPP for a 3-year media and creative partnership.
Regeneron Pharmaceuticals' SVP Controller Jason Pitofsky sold 4,062 shares on November 4, 2026, at $942.21 per share, totaling $3.8M. He now directly owns 4,272 shares and indirectly owns 48 shares. The transaction was disclosed in an SEC Form 4 filing.
Pitofsky Jason (SVP Controller) sold 179 indirectly-held shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $950.76 ($0.17M total) on 2026-11-04.
Over the past 7 days, AlphAI's AI scored 19 news stories mentioning REGN (REGENERON PHARMACEUTICALS, INC.). Coverage has skewed bullish: 15 bullish, 4 neutral, and 0 bearish.
Recent REGN coverage spans insider activity, financial news and earnings.
In the last 30 days, REGN insiders filed 57 SEC Form 4 transactions — no purchases and 57 sales ($49.6M). The most active reporter was MURPHY ANDREW J, Co-Chief Scientific Officer, with 27 filings. 53% of those filings were made under pre-arranged Rule 10b5-1 plans.
Robust earnings and partnership expansion support a bullish view.
Regeneron Pharmaceuticals' SVP Controller Jason Pitofsky sold 4,062 shares on November 4, 2026, at $942.21 per share, totaling $3.8M. He now directly owns 4,272 shares and indirectly owns 48 shares. The transaction was disclosed in an SEC Form 4 filing.
The insider sale may cause slight downward pressure on REGN.
The insider sale may signal reduced confidence, creating modest downward pressure on REGN.
Regeneron Pharmaceuticals director Huda Y. Zoghbi sold 7,439 shares for $7.22M at prices of $970.42 and $971.06 per share, according to an SEC filing. She now directly owns 1,703 shares.
AlphAI scores every news story that mentions REGN with an AI model for sentiment and relevance, and aggregates insider trades from REGENERON PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pfizer reported Q3 revenue of $16.6bn, raising its 2026 revenue guidance to $62bn-$64bn. Regeneron reported a 36% revenue increase to $5.1bn. The Lancet warns of accelerating health impacts of climate change. Cancer Research UK partners with WPP for a 3-year media and creative partnership.
Regeneron Pharmaceuticals' SVP Controller Jason Pitofsky sold 4,062 shares on November 4, 2026, at $942.21 per share, totaling $3.8M. He now directly owns 4,272 shares and indirectly owns 48 shares. The transaction was disclosed in an SEC Form 4 filing.
Pitofsky Jason (SVP Controller) sold 179 indirectly-held shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $950.76 ($0.17M total) on 2026-11-04.
Pitofsky Jason (SVP Controller) sold 3,883 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $941.79 ($939.57–$945.61, $3.66M total) across 7 trades on 2026-11-04.
Regeneron Pharmaceuticals director Huda Y. Zoghbi sold 7,439 shares for $7.22M at prices of $970.42 and $971.06 per share, according to an SEC filing. She now directly owns 1,703 shares.
Zoghbi Huda Y sold 7,439 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $970.46 ($970.42–$971.06, $7.22M total) across 2 trades on 2026-11-03.
Nuvera, an Inizio Engage brand, announced winners of its 2026 Best-in-Class Patient Support Program Awards, with AbbVie, Sanofi/Regeneron, Pfizer, and Genentech among the top large pharma companies across various therapeutic areas. Rankings are based on feedback from over 2,300 physicians and healthcare staff. Winners will be recognized at the Informa Patient Pathways Congress in November. Nuvera also noted the increasing role of AI in patient support programs.
FDA accepted uniQure's Huntington disease gene therapy application, with a decision expected in May 2027. AV-1959R (Nuravax) received fast track designation for Alzheimer's prevention. FDA decisions are pending on Bayer's asundexian and Regeneron's cemdisiran. Bristol Myers Squibb reported a patient death in MS trials. Novartis' remibrutinib showed relapse rate reductions in MS trials but no significant disability progression impact.
SING GEORGE L sold 21,129 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $964.38 ($960.57–$970.18, $20.38M total) across 9 trades on 2026-11-02.
POON CHRISTINE A sold 7,830 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $969.09 ($966.74–$971.31, $7.59M total) across 6 trades on 2026-11-02.
